| FORM 990, PART III, LINE 4A |
RESEARCH PROGRAM $26,550,891 GRANTS $25,469,007 THE FOUNDATION'S MISSION IS TO ADVANCE THE BEST SCIENCE TO TRANSFORM PANCREATIC CANCER INTO A CURABLE DISEASE. TO MOVE PROGRESS TOWARD THIS GOAL, THE FOUNDATION COMMITTED AN ADDITIONAL $25 MILLION TO RESEARCH DURING FY2022, BRINGING THE CUMULATIVE TOTAL INVESTED THROUGH JUNE 2022 TO $250 MILLION. BECAUSE RESEARCH IS FUNDAMENTAL AND PROGRESS IS PARAMOUNT, THE FOUNDATION HAS SUPPORTED NEARLY 320 PROJECTS WORLDWIDE, WITH PARTNERSHIPS AT MORE THAN 80 ACADEMIC INSTITUTIONS. DURING FY2022, MAJOR LUSTGARTEN-FUNDED RESEARCH MILESTONES AND ACHIEVEMENTS HAVE FOCUSED ON: STRETCHING THE BOUNDARIES OF SCIENCE THROUGH CLINICAL TRIALS: THE FOUNDATION ESTABLISHED THE CLINICAL ACCELERATOR INITIATIVE (CAI) TO SHORTEN THE TIME FROM CLINICAL TRIAL CONCEPT TO LAUNCH USING A LUSTGARTEN-DEVELOPED PROCESS BASED ON THE BEST AVAILABLE SCIENCE AND EMPLOYING CUTTING-EDGE BIOMARKERS. THESE "SMARTER" CLINICAL TRIALS WILL GENERATE LARGE VOLUMES OF DATA THAT SCIENTISTS CAN USE NOW AND, IN THE FUTURE, TO INFORM AND IMPROVE CLINICAL TRIALS AND EXPEDITE NEW TREATMENTS. IN 2022, THE FOUNDATION APPROVED $1.5 MILLION TO FUND ONE CAI CLINICAL TRIAL BASED AT MASSACHUSETTES GENERAL HOSPITAL AND $3.3 MILLION TO SUPPORT THE DEVELOPMENT OF A DEDICATED CLINICAL SCIENCE DATABASE WITH THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. THE TRANSLATIONAL ADVISORY GROUP, LED BY CHIEF MEDICAL ADVISOR DR. ELIZABETH JAFFEE AND COMPRISED OF RENOWNED PANCREATIC CANCER EXPERTS, GUIDES THE CAI BY IDENTIFYING, REVIEWING AND DEVELOPING THE BEST TRANSLATIONAL PROJECTS TO IMPACT PATIENT CARE IN THE CLINIC. THE TRANSLATIONAL ADVISORY GROUP IS BUILDING A NETWORK OF SITES TO EXECUTE THE PROPOSED RESEARCH IN SMALL CLINICAL TRIALS OF 10-20 PATIENTS EACH. THESE SCIENCE-DRIVEN STUDIES COULD DRAMATICALLY INFORM RESEARCH, ENABLING INVESTIGATORS TO QUICKLY DETERMINE IF PATIENTS ARE RESPONDING TO SPECIFIC TREATMENT APPROACHES AND WHY - INFORMATION THAT WILL HELP ENHANCE CLINICAL TRIALS AND ULTIMATELY, CLINICAL CARE. LUSTGARTEN ADVANCING BREAKTHROUGH SCIENCE (LABS) PROGRAM: A HALLMARK OF THE LUSTGARTEN FOUNDATION'S UNIQUE RESEARCH STRATEGY, THE LABS PROGRAM PROVIDES LONG-TERM FUNDING TO PROMOTE THE DEVELOPMENT OF INNOVATIVE IDEAS AND SPEED THE PACE OF DISCOVERY BY INCENTIVIZING INTERDISCIPLINARY TEAM SCIENCE. THE LABS PROGRAM IS COMMITTED TO SHARING EXPERTISE ACROSS DIVERSE FIELDS, WITH THE GOAL OF ADVANCING KNOWLEDGE AND REFINING OUR COLLECTIVE UNDERSTANDING OF COMPLEX SYSTEMS AND PATHWAYS. THE SIX LABS PROGRAM SITES ARE: - COLD SPRING HARBOR LABORATORY (LONG ISLAND, NEW YORK) FOCUSING ON PERSONALIZED MEDICINE, DR. DAVID TUVESON LEADS THE LABS SITE AT COLD SPRING HARBOR LABORATORY, DESIGNING NEW MODELS OF THE DISEASE AND DISCOVERING NOVEL THERAPEUTIC AND DIAGNOSTIC PLATFORMS TO BRING NEW OPTIONS TO PATIENTS MORE RAPIDLY. DR. TUVESON WAS THE FIRST SCIENTIST TO DEVELOP A PANCREATIC CANCER ORGANOID - A THREE-DIMENSIONAL CELL CULTURE SYSTEM WHICH REPRODUCES A PATIENT'S TUMOR. THIS ENABLES RESEARCHERS TO REPEATEDLY TEST THE EFFECTIVENESS OF DIFFERENT DRUGS TO ACCURATELY PREDICT HOW A PATIENT WILL RESPOND TO VARIOUS THERAPIES, OFFERING THE HOPE OF PERSONALIZED CANCER TREATMENTS. IN ADDITION TO OTHER PROJECTS, THE LAB'S ORGANOID FACILITY IS GROWING AND TESTING ORGANOIDS FOR THE ONGOING PASS-01 CLINICAL TRIAL. - DANA-FARBER CANCER INSTITUTE (BOSTON, MASSACHUSETTS) LEARNING FROM PATIENTS TO ADVANCE RESEARCH UNDER THE LEADERSHIP OF DR. BRIAN WOLPIN, THE LABS SITE AT DANA-FARBER IS A CRITICAL HUB FOR ADVANCING RESEARCH FROM THE LABORATORY TO THE CLINIC, INITIATING SCIENTIFICALLY-DRIVEN CLINICAL TRIALS AND IDENTIFYING NEW APPROACHES TO EARLY INTERCEPTION/DETECTION. DR. WOLPIN AND HIS TEAM ARE ALSO ANALYZING PANCREATIC CANCER SUBTYPES TO UNDERSTAND MECHANISMS OF DRUG RESISTANCE AND THE GENETIC DRIVERS THAT DETERMINE EACH SUBTYPE. HE IS EVALUATING NEW, PERSONALIZED TREATMENT APPROACHES BASED ON MOLECULAR AND FUNCTIONAL CHARACTERIZATION OF THE PATIENT'S TUMOR. - JOHNS HOPKINS (BALTIMORE, MARYLAND) GUIDED BY GENETICS, FOCUSED ON PANCREATIC CANCER DIRECTED BY DR. BERT VOGELSTEIN, THE LABS SITE AT JOHNS HOPKINS IS USING ITS EXPERTISE IN EARLY DETECTION AND INTERCEPTION OF PANCREATIC CANCER TO DISCOVER PANCREATIC CANCER AT AN EARLIER STAGE, WHEN PATIENTS MAY BE SURGICAL CANDIDATES, AND IS DEVELOPING NEW THERAPEUTIC APPROACHES BASED ON GENETIC ALTERATIONS. IN 2021, EXACT SCIENCES ACQUIRED THE RIGHTS TO CANCERSEEK, A POWERFUL BLOOD TEST CAPABLE OF DETECTING THE EARLY PRESENCE OF MULTIPLE CANCERS AND DEVELOPED THROUGH LUSTGARTEN FUNDING AT THE JOHNS HOPKINS LABS SITE. EXACT SCIENCES IS PREPARING TO INITIATE A 100,000-PERSON REGISTRATION TRIAL AS A STEP TOWARD FDA APPROVAL. (PLEASE SEE EARLY EVENTS OF PANCREATIC CANCER WITHIN THIS DOCUMENT FOR MORE INFORMATION ON EARLY DETECTION ADVANCEMENTS.) - JOHNS HOPKINS (BALTIMORE, MARYLAND) ADVANCING IMMUNOLOGY LED BY DR. ELIZABETH JAFFEE, THE SECOND LABS SITE AT JOHNS HOPKINS IS WORKING TO BRING NOVEL THERAPIES FOR PANCREATIC CANCER TO THE CLINIC AS QUICKLY AS POSSIBLE. BUILDING ON DECADES OF EXPERIENCE AND EXPERTISE IN THE IMMUNOLOGY OF PANCREATIC CANCER, DR. JAFFEE AND HER TEAM ARE FOCUSING ON IMMUNE THERAPIES AND DEVELOPING APPROACHES TO BRING THE BENEFITS OF THIS REVOLUTIONARY APPROACH TO TREATING TUMORS TO PANCREATIC CANCER. - MASSACHUSETTS INSTITUTE OF TECHNOLOGY (CAMBRIDGE, MASSACHUSETTS) USING TECHNOLOGY TO INCREASE PRECISION IN PANCREATIC CANCER RESEARCH THE LABS SITE AT MIT IS LEVERAGING ITS UNPARALLELED EXPERTISE IN CANCER BIOLOGY AND ENGINEERING TO ADVANCE PANCREATIC CANCER RESEARCH. LED BY DR. TYLER JACKS, THE LABORATORY IS STUDYING GENETIC EVENTS CONTRIBUTING TO CANCER DEVELOPMENT AND EXAMINING THE IMMUNE RESPONSES TO THE DISEASE USING MOLECULAR PROFILING TO IDENTIFY TUMOR MUTATIONS. DR. JACKS AND HIS TEAM ALSO ARE RUNNING PRECLINICAL TRIALS IN MOUSE MODEL SYSTEMS TO SEE WHICH DRUGS AND DRUG COMBINATIONS WORK BEST TO BRING ABOUT A PROPER IMMUNE RESPONSE AGAINST PANCREATIC CANCER. - SALK INSTITUTE FOR BIOLOGICAL STUDIES (LA JOLLA, CALIFORNIA) NEW APPROACHES, NEW TARGETS THE LABS (LUSTGARTEN ADVANCING BREAKTHROUGH SCIENCE) SITE AT THE SALK INSTITUTE IS LED BY FOUR CO-PRINCIPAL INVESTIGATORS: PROFESSORS REUBEN SHAW, RONALD EVANS, TONY HUNTER, AND DANNIELLE ENGLE. THESE RESEARCHERS AND THEIR TEAMS ARE EXPLORING UNIQUE AND UNDERSTUDIED AREAS RELATED TO DIAGNOSING AND TREATING PANCREATIC CANCER AND ARE FOCUSED ON IDENTIFYING AND VALIDATING NEW TARGETS FOR PANCREATIC CANCER DRUGS AND BIOMARKERS. REUBEN SHAW, PROFESSOR IN THE MOLECULAR AND CELL BIOLOGY LABORATORY AND WILLIAM R. BRODY CHAIR, EXPLORES THE ROLE OF LIPID METABOLISM. RONALD EVANS, PROFESSOR IN THE GENE EXPRESSION LABORATORY AND MARCH OF DIMES CHAIR IN MOLECULAR AND DEVELOPMENT BIOLOGY, INVESTIGATES TRANSCRIPTIONAL AND EPIGENETIC TARGETS. TONY HUNTER, AMERICAN CANCER SOCIETY PROFESSOR IN THE MOLECULAR AND CELL BIOLOGY LABORATORY AND RENATO DULBECCO CHAIR, WILL CONTINUE HIS RENOWNED EXPLORATION OF KINASE DRUG TARGETS. DANNIELLE ENGLE, ASSISTANT PROFESSOR IN THE REGULATORY BIOLOGY LABORATORY, ADDRESSES VULNERABILITIES IN GLYCANS, CARBOHYDRATES THAT COAT PROTEINS AND CELLS. MICHAEL DOWNES, SENIOR STAFF SCIENTIST IN THE GENE EXPRESSION LABORATORY, WILL OVERSEE THE CENTRAL CORE FACILITY STUDYING CHANGES IN PANCREATIC CANCER, AND DEVELOPING NEW MODELS AND THERAPEUTIC APPROACHES. |
| FORM 990, PART III, LINE 4A |
UNDERSTANDING THE EARLY EVENTS OF PANCREATIC CANCER: ALISON KLEIN, PHD, JOHNS HOPKINS SCHOOL OF MEDICINE, IS USING UPDATED WAYS OF SEQUENCING GENES TO DETERMINE IF THERE ARE OTHER GENES BESIDES THE ONES ALREADY KNOWN TO INCREASE THE RISK FOR PANCREATIC CANCER IN FAMILIES. THIS IS CRITICAL BECAUSE IN APPROXIMATELY 80% OF FAMILIES WITH INHERITED PANCREATIC CANCER, THE GENE CAUSING THE RISK IS UNKNOWN. DR. KLEIN AIMS TO IDENTIFY GENETIC CAUSES OF FAMILIAL PANCREATIC CANCER; DISCOVER NEW CANDIDATE PANCREATIC CANCER GENES THAT WERE NOT FOUND USING SHORT-READ SEQUENCING; IDENTIFY FAMILIES WITH GENETIC VARIANTS IN KNOWN PANCREATIC CANCER GENES THAT WERE MISSED USING CONVENTIONAL SEQUENCING APPROACHES; CREATE NEW ALGORITHMS TO IDENTIFY THE CAUSE OF INHERITED DISEASE INCLUDING CANCERS; AND DEVELOP EFFECTIVE METHODS FOR LARGE-SCALE, LONG-RANGE GENOMIC SEQUENCING SO DOCTORS CAN MONITOR FOR RISK IN THEIR PATIENTS. LAURA WOOD, MD, PHD, JOHNS HOPKINS UNIVERSITY, DEVELOPED CODA, A THREE-DIMENSIONAL MODELING TECHNIQUE USING SLICES OF TISSUES TO BUILD A MODEL SHOWING WHAT HAPPENS WHEN CELLS TOUCH OTHER CELLS TO DETERMINE IF THAT INTERACTION HAS AN IMPACT ON PANCREATIC CANCER DEVELOPMENT. USING CODA, SHE WILL ANALYZE NORMAL PANCREATIC TISSUE AND EXAMINE THE SPECIFIC CELLULAR AND MOLECULAR CHANGES THAT OCCUR IN OLDER PATIENTS WHO ARE AT AN INCREASED FAMILIAL RISK. DR. WOOD IS ALSO EXAMINING PEOPLE WITH PRECANCEROUS LESIONS CALLED PANINS TO UNDERSTAND WHAT CAUSES A LESION TO CHANGE FROM BENIGN, WHICH REQUIRES MONITORING, TO MALIGNANT, WHICH REQUIRES SURGICAL INTERVENTION. IDENTIFYING NOVEL THERAPEUTIC APPROACHES: THE FOUNDATION'S THERAPEUTICS-FOCUSED RESEARCH PROGRAM WAS CREATED TO ENSURE A ROBUST AND FLOURISHING PIPELINE OF POTENTIAL TREATMENTS AND TO ENABLE COLLABORATION. TO DATE, THE THERAPEUTICS-FOCUSED RESEARCH PROGRAM HAS AWARDED 10 GRANTS TOTALING $11.2 MILLION. FUNDED PROJECTS ADDRESS FOUR KEY AREAS OF PANCREATIC CANCER BIOLOGY: - LEARNING HOW THE STROMA - THE SUPPORTIVE TISSUE SURROUNDING THE PANCREATIC TUMOR - MAY HELP PROTECT TUMORS FROM THE IMMUNE SYSTEM AND RESIST THERAPIES. - UNDERSTANDING AND DISCOVERING HOW TO BLOCK THE INFLAMMATORY SIGNALS THAT CAN LEAD TO PANCREATIC CANCER AND OTHER PANCREATIC DISEASES IN RESPONSE TO ENVIRONMENTAL CAUSES. - DETERMINING WAYS TO STOP TUMOR CELL GROWTH BY BLOCKING THE ABNORMAL METABOLIC PATHWAYS USED BY PANCREATIC CANCER CELLS. - PREVENTING THE SPREAD - OR METASTASIS - OF CANCER BY ISOLATING METASTATIC TRIGGERS IN CANCER CELLS AND THE STROMA. EXPANDING COLLABORATION WITH STAND UP TO CANCER: THE PANCREATIC CANCER COLLECTIVE (PCC), A JOINT INITIATIVE OF THE LUSTGARTEN FOUNDATION AND STAND UP TO CANCER, IS MAKING GROUNDBREAKING PROGRESS IN IDENTIFYING NEW WAYS TO TREAT PANCREATIC CANCER AND IMPROVING OUTCOMES FOR PATIENTS. THE COLLECTIVE HAS SUPPORTED RESEARCH LED BY MORE THAN 400 RESEARCH INVESTIGATORS AT APPROXIMATELY 70 PARTICIPATING INSTITUTIONS INCLUDING NEARLY 30 CLINICAL TRIALS. IN FY22, THE COLLECTIVE FUNDED THE FOLLOWING NEW RESEARCH: AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) 2022 ANNUAL MEETING, VINOD BALACHANDRAN, MD, MEMORIAL SLOAN KETTERING CANCER CENTER, PRESENTED HIS RESULTS OF THE FIRST TRIAL TESTING A PERSONALIZED MESSENGER RNA (MRNA) VACCINE. THE PHASE 1 TRIAL WAS THE CULMINATION OF YEARS OF RESEARCH LEADING TO THE CRITICAL DISCOVERY THAT LONG-TERM PANCREATIC CANCER SURVIVORS HAVE SPECIFIC IMMUNE RESPONSES THE TEAM HOPED TO MIMIC WITH THE VACCINES. THE ASCO PRESENTATION FOLLOWED THE TEAM'S SECOND PAPER PUBLISHED IN THE SCIENTIFIC JOURNAL NATURE (6/9/22). THE RESULTS SUGGEST THE POSSIBILITY OF DURABLE PROTECTION AGAINST PANCREATIC CANCER IF AN IMMUNE RESPONSE CAN BE DRIVEN AGAINST TUMOR-SPECIFIC TARGETS. THE STUDY ALSO DEMONSTRATES THE FEASIBILITY OF DEVELOPING PATIENT-SPECIFIC, PERSONALIZED VACCINES IN A CLINICALLY RELEVANT TIMEFRAME. ELIZABETH JAFFEE, MD, JOHNS HOPKINS, THE LUSTGARTEN FOUNDATION'S CHIEF MEDICAL ADVISOR, DIRECTS THE FIRST-EVER VACCINE TRIAL AIMED AT PREVENTING PANCREATIC CANCER IN HEALTHY INDIVIDUALS WITH AN ELEVATED RISK FOR THE DISEASE BASED ON THEIR GENETICS OR FAMILY HISTORY OF PANCREATIC CANCER. DR. JAFFEE'S STUDY IS ENROLLING 25 PARTICIPANTS AND WILL MEASURE THE SAFETY AND IMMUNE RESPONSE TO A VACCINE AGAINST MUTANT KRAS PROTEINS, THE MOST COMMON DRIVER OF PANCREATIC CANCER. IF DEEMED SAFE AND EFFECTIVE, THE NEXT STEP IS TO DETERMINE IF IMMUNITY AGAINST THIS MUTATED PROTEIN IS ABLE TO DELAY OR PREVENT PANCREATIC CANCER. ADDRESSING EQUITY, DIVERSITY, AND INCLUSION IN PANCREATIC CANCER RESEARCH: SOLVING THE COMPLEX PROBLEM OF PANCREATIC CANCER REQUIRES DIVERSITY OF THOUGHT, EDUCATION, TRAINING, BACKGROUND AND EXPERIENCE TO MOVE PROGRESS FORWARD. OUR COMMITMENT TO ENSURING EQUITY, DIVERSITY AND INCLUSION - ACROSS LUSTGARTEN-FUNDED RESEARCH AND THE SCIENTISTS WE SUPPORT - IS FOUNDATIONAL TO OUR MISSION TO CURE PANCREATIC CANCER. SUPPORTING DISTINGUISHED EARLY-CAREER SCIENTISTS HELPS ENSURE THEIR CONTINUED COMMITMENT TO STUDYING PANCREATIC CANCER. THE LUSTGARTEN FOUNDATION GRANTED TWO CAREER DEVELOPMENT AWARDS TO INCREASE THE NUMBER OF EARLY-CAREER WOMEN AND UNDERREPRESENTED SCIENTISTS RECEIVING FUNDING FOR PANCREATIC CANCER RESEARCH. THE AWARDS PROGRAM, IN ITS SECOND YEAR, CONTINUES TO SUPPORT INVESTIGATORS COMMITTED TO INCREASING OUR UNDERSTANDING AND TREATMENT OF THIS DISEASE. THE AWARDS HONOR THE LIVES AND LEGACIES OF TWO TRAILBLAZING AMERICANS LOST TO PANCREATIC CANCER - JUSTICE RUTH BADER GINSBURG AND CONGRESSMAN JOHN ROBERT LEWIS. EACH RECIPIENT IS AWARDED A THREE-YEAR, $300,000 GRANT FOR THEIR PANCREATIC CANCER RESEARCH. - 2022 CAREER DEVELOPMENT AWARD IN HONOR OF RUTH BADER GINSBURG WAS GRANTED TO PINGPING HOU, PHD, AN ASSISTANT PROFESSOR AT RUTGERS UNIVERSITY. DR. HOU IS INVESTIGATING AN IMMUNE CELL POPULATION CALLED TUMOR ASSOCIATED MACROPHAGES (TAMS) THAT HAVE BEEN SHOWN TO CAUSE RESISTANCE IN A THERAPY TARGETING KRAS, A KEY DRIVER OF PANCREATIC CANCER. - 2022 CAREER DEVELOPMENT AWARD IN HONOR OF JOHN ROBERT LEWIS WAS GRANTED TO EDWIN MANUEL, PHD, AN ASSISTANT PROFESSOR AT THE BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE. DR. MANUEL IS DEVELOPING NEW METHODS TO COMBAT PANCREATIC CANCER THERAPEUTIC RESISTANCE AND ADAPTATION, KEY COMPONENTS LEADING TO DISEASE PROGRESSION. PARTNERING WITH BREAK THROUGH CANCER TO ADVANCE KRAS RESEARCH: COMMITTED TO DEVELOPING A THERAPY TARGETING KRAS, A GENE MUTATED IN 90% OF PANCREATIC CANCER CASES, THE LUSTGARTEN FOUNDATION INVESTED $5 MILLION IN SUPPORT OF A 3-YEAR, $15 MILLION PROJECT WITH BREAK THROUGH CANCER ENTITLED "CONQUERING KRAS IN PANCREATIC CANCER." RESEARCHERS WILL INVESTIGATE PROMISING KRAS-TARGETING THERAPIES TO ACCELERATE THE TRANSLATION OF NEW KRAS INHIBITORS INTO EFFECTIVE DRUGS FOR THIS DISEASE. BREAK THROUGH CANCER CREATED A "TEAM LAB" STRUCTURE TO MAXIMIZE INTERDISCIPLINARY COLLABORATION AMONG RESEARCHERS FROM THE NATION'S TOP FIVE CANCER RESEARCH CENTERS (DANA-FARBER CANCER INSTITUTE, JOHNS HOPKINS, MEMORIAL SLOAN KETTERING CANCER CENTER, KOCH INSTITUTE FOR INTEGRATIVE CANCER RESEARCH AT MIT, AND THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER). THEY WILL WORK TOGETHER TO BOLDLY TACKLE THE BIGGEST CHALLENGES IN CANCER, WITH A FOCUS ON PANCREATIC CANCER, OVARIAN CANCER, AND GLIOBLASTOMA, WHICH ALL FACE POOR PROGNOSES AND SLOW RESEARCH PROGRESS. |
| FORM 990, PART III, LINE 4B |
PUBLIC EDUCATION AND INFORMATION PROGRAM $677,642 THE LUSTGARTEN FOUNDATION IS THE LARGEST PRIVATE FUNDER OF PANCREATIC CANCER RESEARCH IN THE WORLD, FUNDING PREEMINENT PANCREATIC CANCER RESEARCHERS, DRIVING THE PURSUIT OF BOLD AND INNOVATIVE SCIENCE TOWARD EARLIER DETECTION AND BETTER TREATMENTS, TRANSFORMING PANCREATIC CANCER INTO A CURABLE DISEASE. THE FOUNDATION FUNDS RESEARCH WHERE CREATIVE RISKS YIELD HIGH REWARDS TO ACCELERATE AND EXPAND LIFE-SAVING TREATMENT OPTIONS. WE BELIEVE TIME IS EVERYTHING TO PATIENTS AND THEIR FAMILIES, AND THAT COMMUNITY IS POWER. LUSTGARTEN PROGRAMS AND EVENTS PROVIDE PEOPLE AFFECTED BY PANCREATIC CANCER A VOICE AND A PLACE TO CREATE HOPE, TOGETHER. 100% OF ALL DONATIONS FUEL THE RESEARCH TO ADVANCE UNDERSTANDING OF THIS COMPLEX, DEVASTATING AND UNDERFUNDED CANCER. THE LUSTGARTEN FOUNDATION CREATED, PRINTED AND DISTRIBUTED MATERIALS TO UPDATE PATIENTS, CAREGIVERS, SURVIVORS, DONORS, VOLUNTEERS, WALK AND EVENT LEADERS AND CORPORATE SPONSORS ON RESEARCH DEVELOPMENTS, FOUNDATION MILESTONES AND WALKS/EVENTS. MATERIALS INCLUDED: - LUSTGARTENLIVE! SERIES OF RESEARCH-FOCUSED, INTERACTIVE WEBINARS - PROGRESS & PROMISE NEWSLETTERS - ANNUAL REPORT - MONTHLY E-NEWSLETTER WITH VIDEO INTRODUCTION - RESEARCH MILESTONES UPDATE -TIMELINE OF PANCREATIC CANCER RESEARCH MILESTONES - INCREASED FOCUS ON VIDEO, INCLUDING A VIRTUAL TOUR OF THE LUSTGARTEN LAB AT COLD SPRING HARBOR LABORATORY - PANCREATIC CANCER COLLECTIVE RADIO AND DIGITAL PUBLIC SERVICE ANNOUNCEMENTS FOCUSED ON INCREASING DIVERSITY IN CLINICAL TRIALS. WE ALSO CONTINUE DISTRIBUTING OUR NAVIGATING PANCREATIC CANCER: A GUIDE FOR PATIENTS & CAREGIVERS HANDBOOK, CONTAINING INFORMATION ON MANAGING A PANCREATIC CANCER DIAGNOSIS AND TREATMENT. THE BOOK AND MANY OF THE MATERIALS NOTED ABOVE ARE ACCESSIBLE AT WWW.LUSTGARTEN.ORG. |
| FORM 990, PART III, LINE 4C |
PROFESSIONAL EDUCATION PROGRAM $817,430 PROFESSIONAL EDUCATION FOCUSED ON THE FOUNDATION'S SENIOR LEADERSHIP CONDUCTING HIGH-LEVEL MEETINGS WITH SCIENTISTS, DIRECTORS OF THE DEDICATED LABORATORIES AND COLLABORATING ORGANIZATIONS AS WELL AS ATTENDING/PRESENTING VIRTUALLY AT SCIENTIFIC MEETINGS FOR ORGANIZATIONS INCLUDING THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) AND STAND UP TO CANCER. THE FOUNDATION BEGAN PREPARING FOR ITS ROLE AS A LEAD SPONSOR FOR THE AACR SPECIAL MEETING ON PANCREATIC CANCER THAT WAS HELD IN BOSTON, MA IN SEPTEMBER 2022. THE FOUNDATION ALSO STARTED PREPARING FOR ITS ANNUAL SCIENTIFIC MEETING FOR THE SCIENTIFIC ADVISORY BOARD AND SELECT RESEARCHERS IN THE BANBURY CENTER AT COLD SPRING HARBOR LABORATORY THAT WAS HELD IN OCTOBER 2022. THESE MEETINGS HELP FOSTER COLLABORATION AND A BETTER UNDERSTANDING OF GLOBAL DEVELOPMENTS IN PANCREATIC CANCER RESEARCH AND PROGRESS/TRENDS TO HELP SHAPE THE FOUNDATION'S ANNUAL RESEARCH PROGRAM AND LONG-TERM STRATEGIC GOALS. |
| FORM 990, PART VI, SECTION A, LINE 2 |
CHARLES F. DOLAN, JAMES L. DOLAN AND QUENTIN DOLAN - FAMILY AND BUSINESS RELATIONSHIP. MARCIA LUSTGARTEN, ANDREW LUSTGARTEN AND JESSICA LUSTGARTEN COURTEMANCHE - FAMILY RELATIONSHIP. ANDREW LUSTGARTEN, JAMES L. DOLAN, PHILIP D'AMBROSIO, AND QUENTIN DOLAN - BUSINESS RELATIONSHIP. |
| FORM 990, PART VI, SECTION B, LINE 11B |
FORM 990 IS REVIEWED BY THE PRESIDENT FOR ACCURACY AND REASONABLENESS PRIOR TO SUBMISSION TO THE IRS. ADDITIONALLY A COMPLETE COPY OF THE FINAL RETURN IS PROVIDED TO ALL VOTING BOARD MEMBERS PRIOR TO FILING WITH THE IRS. |
| FORM 990, PART VI, SECTION B, LINE 12C |
THE ORGANIZATION HAS A WRITTEN CONFLICT OF INTEREST POLICY. THE WRITTEN POLICY REQUIRES ANNUAL DISCLOSURES BY ALL MEMBERS OF THE BOARD OF DIRECTORS, OFFICERS, AND KEY PERSONS OF ANY INTEREST THAT COULD GIVE RISE TO CONFLICT. THE ORGANIZATION REGULARLY AND CONSISTENTLY MONITORS AND ENFORCES THE COMPLIANCE OF THE CONFLICT OF INTEREST POLICY. IN THE INSTANCE WHERE A DIRECTOR HAS A CONFLICT, THEY ARE ASKED BY THE BOARD CHAIR TO RECUSE THEMSELVES FROM DELIBERATIONS, DECISIONS AND THE VOTE. |
| FORM 990, PART VI, SECTION B, LINE 15 |
COMPENSATION FOR THE CHIEF EXECUTIVE OFFICER AND THE PRESIDENT WAS REVIEWED AND APPROVED BY THE INDEPENDENT MEMBERS OF THE BOARD OF DIRECTORS IN 2021. THE REVIEW WAS UNDERTAKEN BY A THIRD-PARTY HUMAN RESOURCES CONSULTANT AND INCLUDED THE USE OF COMPARABILITY DATA WHICH WAS CONTEMPORANEOUSLY DOCUMENTED. |
| FORM 990, PART VI, SECTION C, LINE 19 |
AUDITED FINANCIAL STATEMENTS ARE MADE AVAILABLE ON THE ORGANIZATION'S WEBSITE. IN ADDITION, GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND AUDITED FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST. |
Attach to Form 990 or 990-EZ.